Chat with us, powered by LiveChat

Ankylosing Spondylitis Drugs Market (Drug Class - NSAIDs, TNF Inhibitors, Immunosuppressive Drugs, TNF Blockers, JAK Inhibitors, Steroids, and Others; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Ankylosing Spondylitis Drugs Market (Drug Class - NSAIDs, TNF Inhibitors, Immunosuppressive Drugs, TNF Blockers, JAK Inhibitors, Steroids, and Others; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0404 Category: Healthcare & Medical Devices Published: December, 2023

A recent report published by Infinium Global Research on ankylosing spondylitis drugs market provides in-depth analysis of segments and sub-segments in the global as well as regional ankylosing spondylitis drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional ankylosing spondylitis drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global ankylosing spondylitis drugs market.

Market Insight:

The global ankylosing spondylitis drugs market was valued at USD 5.5 billion in 2022 and is expected to reach USD 10.92 billion in 2030, with a CAGR of 9.05% during the forecast period 2023-2030.

The Ankylosing Spondylitis (AS) drugs market is nothing, but the pharmaceutical sector focused on medications and treatments that are mainly designed to manage and lighten the symptoms of ankylosing spondylitis. It is a chronic inflammatory disease mostly affecting the spine and large joints. The market includes a range of drugs such as Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), biologics, and other therapies. These drugs are aimed at inflammation, reducing pain, and slowing disease progression for individuals suffering from AS. The market players are investing in research and development of AS drugs. to discover new treatments and improve the results of existing therapies, which support the AS drugs market's expansion near future.

The Ankylosing Spondylitis (AS) drugs market is expected to grow due to the advancements in medical biologics during the projected period. Ongoing advancement in biologic therapies which is developed to target the underlying mechanisms of ankylosing spondylitis. The innovations in biologics, such as TNF inhibitors and other targeted therapies, have revolutionized the treatment landscape. These drugs offer improved efficacy, reduced side effects, and better disease management, thereby significantly driving market growth. Continuous research and development efforts taken by market players to create more specific, effective, and safer biological drugs for AS further contribute to the growth of the market. Additionally, the rising awareness regarding AS among the general population and its treatment significantly contributes to the market's growth. The increasing awareness regarding AS leads to earlier diagnoses, which further drives the demand for effective treatments, and positively impacts market growth. However, the requirement of a high budget to carry out research and development of AS drugs, coupled with the difficult regulatory approval process, may hamper the market growth. Furthermore, the expansion of the healthcare sector and the rising focus on research and development activity offer lucrative growth opportunities for the AS drugs market in the upcoming years.

Ankylosing Spondylitis Drugs Market Size, Share, Trends | IGR

North America holds a significant market share in the AS drug market during the forecast period. The rising number of patients suffering from ankylosing spondylitis and the rising number of companies that work in manufacturing and developing AS drugs for treating patients are the primary reasons behind the dominance of the North America AS drug market. Secondly, the region's highly advanced healthcare infrastructure is contributing to the growth of the market. Moreover, the global ankylosing spondylitis market in the Asia Pacific region is anticipated to grow at the highest growth rate over the forecast period. In the Asia Pacific region, the growth of the AS drugs market is attributed to a noticeable increase in the incidence of ankylosing spondylitis in various developing nations including China, India, and Indonesia. This rising number of patients suffering from AS directly contributes to generating high revenue in ankylosing spondylitis drugs in the region. Moreover, favorable reimbursement policies within developing countries play a pivotal role in the regional growth of the AS drug market during the projected period.

Report Scope of the Ankylosing Spondylitis Drugs Market:

Report Coverage Details
Market Size in 2022 USD 5.5 Billion
Market Size by 2030 USD 10.92 Billion
Growth Rate from 2023 to 2030 CAGR of 9.05%
Largest Market North America
No. of Pages 180
Market Drivers
  • The ankylosing spondylitis drugs market is driven by advancements in medical biologics.

  • The rising awareness among the general population regarding AS and its treatment significantly contributes to the market's expansion.

Market Segmentation By Drug Class, and By Distribution Channel
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global ankylosing spondylitis drugs market covers segments such as drug class, and distribution channel. On the basis of drug class, the sub-markets include NSAIDs, TNF inhibitors, immunosuppressive drugs, TNF blockers, JAK inhibitors, steroids, and others. On the basis of distribution channel, the sub-markets include hospital pharmacy, retail pharmacy, and online pharmacy.

The report provides profiles of the companies in the market such as Pfizer Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, UCB S.A., Belgium, Gilead Sciences, Inc. Johnson & Johnson, Inc., AbbVie Inc., Hetero, Zydus Lifesciences, and Novartis AG.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the ankylosing spondylitis drugs market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global ankylosing spondylitis drugs market was valued at USD 5.5 Billion in 2022.
It is likely to grow at a CAGR of 9.05% during the forecast period 2023-2030.
The global ankylosing spondylitis drugs market is estimated to reach USD 10.92 Billion by the end of 2030.
North America is anticipated to exhibit high demand for ankylosing spondylitis drugs market during the forecast period.
Pfizer Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, UCB S.A., Belgium, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., AbbVie Inc., Hetero, Zydus Lifesciences, and Novartis AG.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.